Involving Antigen-antibody Binding, Specific Binding Protein Assay Or Specific Ligand-receptor Binding Assay Patents (Class 435/7.1)
  • Patent number: 9765380
    Abstract: This disclosure provides ten (10) specific peptides, and particular peptide characteristics, from the cell membrane-bound Her2 protein and a diagnostic assay useful for determining the presence and amount of full length and truncated versions of the full-length Her2 protein in cells derived from formalin fixed paraffin embedded tissue.
    Type: Grant
    Filed: December 8, 2011
    Date of Patent: September 19, 2017
    Assignee: Expression Pathology, Inc.
    Inventor: David Krizman
  • Patent number: 9765135
    Abstract: An objective of the invention is to provide anti-C5 antibodies and methods of using the same. The invention provides anti-C5 antibodies and methods of using the same. In some embodiments, an isolated anti-C5 antibody of the present invention binds to an epitope within the ? chain of C5 with a higher affinity at neutral pH than at acidic pH. The invention also provides isolated nucleic acids encoding an anti-C5 antibody of the present invention. The invention also provides host cells comprising a nucleic acid of the present invention. The invention also provides a method of producing an antibody comprising culturing a host cell of the present invention so that the antibody is produced. The invention further provides a method of producing an anti-C5 antibody comprising immunizing an animal against a polypeptide which comprises the MG1-MG2 domain of the ? chain of C5. Anti-C5 antibodies of the present invention may be for use as a medicament.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: September 19, 2017
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Yoshinao Ruike, Zenjiro Sampei
  • Patent number: 9764078
    Abstract: Some aspects of the invention include methods of treating a patient who has or is at risk of developing kidney disease, methods of selecting a suitable regimen for the prevention or treatment of kidney disease, and to methods of monitoring the effectiveness of a treatment regimen for the prevention or treatment of kidney disease. Other aspects of the invention include medical uses of a binding partner for an anti-IQCJ antibody, and methods of preventing or treating kidney disease in a subject using such binding partners. Still other aspects of the invention include devices for the extracorporeal treatment of a patient's blood.
    Type: Grant
    Filed: June 5, 2015
    Date of Patent: September 19, 2017
    Assignee: The University of Manchester
    Inventor: Paul E. C. Brenchley
  • Patent number: 9765117
    Abstract: Provided are novel peptides having a human minute binding protein-2 (HDM-2) targeting sequence that target the human minute binding protein-2. Also provided are fusion proteins comprising an HDM-2 targeting sequence. Also provided are methods of using the peptides to treat cancer.
    Type: Grant
    Filed: August 9, 2016
    Date of Patent: September 19, 2017
    Inventor: Romek Figa
  • Patent number: 9766254
    Abstract: The invention relates to in vitro method for quantitating the antibodies specific for High mobility group box I (HMGB1) contained in a sample, in particular a serum sample or a cerebrospinal fluid sample obtained from a patient, and the use of this method in the prognostic and/or diagnosis of neurological disorders. These methods are in particular applicable to the monitoring of the human immunodeficiency virus (HIV) infection of a subject who is known to be infected with HIV and in the prognostic and/or diagnostic of the state of progression of Acquired immune deficiency syndrome (AIDS) or the state of progression toward AIDS, in particular the state of progression or the state of progression toward neurological disorders associated with AIDS. Finally, the invention is also about method to determine the immune deficiency or level of immune activation of a patient, in particular a HIV-infected patient.
    Type: Grant
    Filed: September 11, 2015
    Date of Patent: September 19, 2017
    Assignee: INSTITUT PASTEUR
    Inventors: Marie-Lise Gougeon, Beatrice Poirier-Beaudoin, Valerie Seffer, Hela Saidi
  • Patent number: 9758779
    Abstract: The application describes a method of selecting mammalian host cells that express a polypeptide of interest with high yield. The host cells contain an expression cassette with a first polynucleotide encoding a polypeptide of interest, at least one leaky stop codon located downstream of the first polynucleotide and a second polynucleotide located downstream of the leaky codon encoding an immunoglobulin transmembrane anchor comprising a cytoplasmic domain. The host cells are cultivated to allow expression of the polypeptide of interest such that some of the polypeptides of interest are expressed as fusion proteins displayed on the cell surface. High producing cells are then selected based on the presence or amount of the displayed fusion polypeptides.
    Type: Grant
    Filed: August 28, 2009
    Date of Patent: September 12, 2017
    Assignee: Novartis AG
    Inventors: Thomas Jostock, Hans-Peter Knopf, Burkhard Wilms, Audrey Nommay
  • Patent number: 9758579
    Abstract: The present invention is directed to antibodies and fragments thereof and humanized versions thereof having binding specificity for IL-6. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the VH, VL and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-IL-6 antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-IL-6 antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-IL-6 antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with IL-6.
    Type: Grant
    Filed: June 3, 2011
    Date of Patent: September 12, 2017
    Assignee: ALDER BIOHOLDINGS, LLC
    Inventors: Leon Garcia-Martinez, Anne Elisabeth Carvalho Jensen, Katie Olson, Ben Dutzar, Ethan Ojala, Brian Kovacevich, John Latham, Jeffrey T. L. Smith
  • Patent number: 9751909
    Abstract: Processes for synthesis of conformationally restricted nucleomonomers (CRN) by ozonolysis or oxidation of a 2?-vinyl substituted nucleoside precursor with protected 3?-hydroxyl, 4?-hydroxymethyl and 5?-hydroxyl positions. The CRN nucleomonomers can be used to prepare nucleic acid compounds. CRN nucleomonomers for nucleic acid compounds can be prepared in high yields and in multi-gram scale. The nucleic acid compounds can be of various regulatory classes such as antisense RNA for therapeutic modalities useful for treating or preventing diseases or disorders by up- or down-regulating the expression of genes and other nucleic acid based regulatory systems in a cell.
    Type: Grant
    Filed: September 7, 2012
    Date of Patent: September 5, 2017
    Assignee: Marina Biotech, Inc.
    Inventors: Tracy J. Matray, Iwona M. Maciagiewicz, Michael E. Houston, Jr.
  • Patent number: 9752985
    Abstract: For the combinatorial synthesis of molecule libraries, substances are embedded in a matrix consisting of a first solvent thereby forming transport units in a solid state of aggregation at a temperature of less than 90° C. and wherein after application to a support, the physical environment of the transport units is modified by the application of a physical process such as a laser printer whereby the substances in the transport units are linked to the support.
    Type: Grant
    Filed: June 13, 2001
    Date of Patent: September 5, 2017
    Assignees: DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES ÖFFENTLICHEN RECHTS, EUROPÄISCHES LABORATORIUM FÜR MOLEKULARBIOLOGIE
    Inventors: Annemarie Poustka, Frank Breitling, Karl-Heinz Gross, Stefan Dübel, Rainer Saffrich
  • Patent number: 9746472
    Abstract: This invention relates to methods to detect the presence of cancer infiltration of the Central Nervous System (CNS) based on the detection of soluble proteins, preferably, in cerebrospinal fluid samples and vitreous fluid. The invention also relates to kits to perform the methods of the invention.
    Type: Grant
    Filed: July 25, 2012
    Date of Patent: August 29, 2017
    Assignee: UNIVERSIDAD DE SALAMANCA
    Inventor: José Alberto Orfao De Matos Correia E Vale
  • Patent number: 9738711
    Abstract: A method is provided for producing motif-specific, context-independent antibodies that recognize a plurality of peptides or proteins within a genome that contain the same post-translationally modified motif. The method includes the step of immunizing a host with a degenerate peptide library antigen featuring (i) a fixed target motif containing one or more invariant amino acids including at least one modified amino acid, and (ii) a plurality of degenerate amino acids flanking the motif. Motif-specific, context-independent antibodies produced by the disclosed method are also provided. The method encompasses motifs consisting of a single modified amino acid, as well as short motifs comprising multiple invariant amino acids including one or more modified amino acids, such as all or part of kinase consensus substrate motifs, protein-protein binding motifs, or other cell signaling motifs. Methods of using the antibodies, e.g. for genome-wide profiling, are also provided.
    Type: Grant
    Filed: December 17, 2014
    Date of Patent: August 22, 2017
    Assignee: Cell Signaling Technology, Inc.
    Inventors: Michael J. Comb, Yi Tan, Peter Hornbeck
  • Patent number: 9733184
    Abstract: Composite materials comprising a mesoflower structure, methods of preparing the composite material, and methods of detecting heavy metal ion using the composite material are described herein. In some embodiments, a silica-coated gold mesoflower with a layer of silver quantum clusters may be capable of detecting Hg2+ ions in a sample at zeptomolar concentrations.
    Type: Grant
    Filed: August 10, 2012
    Date of Patent: August 15, 2017
    Assignee: Indian Institute of Technology Madras
    Inventors: Pradeep Thalappil, Ammu Mathew, Panikkanvalappil Ravindranathan Sajanlal
  • Patent number: 9732074
    Abstract: Disclosed are small molecule non-peptidic compounds, as well as methods and compositions for the treatment of angiotensin-related diseases and disorders, including cardiovascular diseases, metabolic diseases, gastrointestinal diseases, renal diseases, inflammatory/autoimmune diseases, neurological diseases, bone marrow diseases and cancer.
    Type: Grant
    Filed: March 15, 2014
    Date of Patent: August 15, 2017
    Assignee: University of Southern California
    Inventors: Nicos A. Petasis, Kathleen E. Rodgers, Stan G. Louie, Gere S. DiZerega, Kevin J. Gaffney
  • Patent number: 9734995
    Abstract: A method of mass spectrometry is disclosed wherein the intensity of an analyte is determined by determining the intensity of first characteristic fragment ions when the intensity of the first characteristic fragment ions is within a first intensity range corresponding to the detection or unsaturated range of an ion detector. However, when the intensity of the first characteristic fragment ions is outside of the first intensity range so that the ion detector would saturate then the intensity of the analyte is determined by determining the intensity of second different characteristic fragment ions.
    Type: Grant
    Filed: March 6, 2013
    Date of Patent: August 15, 2017
    Assignee: Micromass UK Limited
    Inventors: Martin Raymond Green, Gareth Rhys Jones, Michael Raymond Morris, Jason Lee Wildgoose
  • Patent number: 9733253
    Abstract: The current disclosure provides for specific peptides from the Secreted Protein Acidic and Rich in Cysteine (SPARC) protein and the derived ionization characteristics of those peptides that are advantageous for quantifying the SPARC directly in formalin fixed biological samples by the method of Selected Reaction Monitoring (SRM) mass spectrometry. Such fixed biological samples include: formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (FFPE) tissue/cells, FFPE tissue blocks and cells from those blocks, and formalin fixed and paraffin embedded tissue culture cells. SPARC protein is quantitated in biological samples by the method of SRM/MRM mass spectrometry by quantitating one or more of the peptides described herein. The peptides can be quantitated if they reside in a modified or an unmodified form. Examples of potentially modified forms of an SPARC peptides include those bearing phosphorylation of a tyrosine, threonine, serine, and/or other amino acid residues within the peptide sequence.
    Type: Grant
    Filed: June 21, 2012
    Date of Patent: August 15, 2017
    Assignee: Expression Pathology, Inc.
    Inventors: David B. Krizman, Todd Hembrough, Sheeno Thyparambil
  • Patent number: 9732121
    Abstract: Compositions and methods are provided relating to HCV E2 protein and modifications thereto which enhance the immunogenicity of the protein for vaccine development with respect to the generation of a neutralizing immune response.
    Type: Grant
    Filed: September 22, 2014
    Date of Patent: August 15, 2017
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Steven Foung, Zhen-Yong Keck, Thomas R. Fuerst
  • Patent number: 9726674
    Abstract: Provided is a monoclonal antibody specifically reactive with a C-terminal neo-epitope of PIIINP comprised in a C-terminal amino acid sequence CPTGXQNYSP-COOH (SEQ ID NO: 4) in which X is Gly or Pro, and where the monoclonal antibody does not recognize or bind an elongated version of the C-terminal amino acid sequence CPTGXQNYSPQZ-COOH (SEQ ID NO: 5), in which Z is absent or is one or more amino acids of the sequence of collagen type III. Also provided is a method of immunoassay for detecting in a biological sample the C-terminal neo-epitope of PIIINP generated by N-protease cleavage of intact type III procollagen, by contacting the sample with the monoclonal antibody, and determining the amount of binding of the antibody.
    Type: Grant
    Filed: April 15, 2014
    Date of Patent: August 8, 2017
    Assignee: Nordic Bioscience A/S
    Inventors: Diana Julie Leeming, Mette Juul Nielsen, Morten Karsdal
  • Patent number: 9726677
    Abstract: Provided herein are novel biomarkers for the identification, prediction or monitoring of fibrotic pulmonary diseases (e.g. idiopathic pulmonary fibrosis (IPF)). The biomarkers provided herein may further be used for therapeutic treatment of IPF.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: August 8, 2017
    Assignee: INTERMUNE, INC.
    Inventors: Karl Kossen, Xiaoli Qin, Sharlene R. Lim, Scott S. Seiwert, Donald Ruhrmund
  • Patent number: 9725751
    Abstract: This invention relates to a device for detecting fungal contamination in an interior environment, including: a concentration module (MC); a separation module (MS) including a chromatographic microcolumn; and a detection module (MD), characterized in that it includes at least one first solenoid valve (E3) upstream of the detection module (MD) enabling either to direct a flow containing target molecules toward the detection module (MD), or to direct a flow filtered by a first means for filtering (Tx1), enabling the detection module (MD) to be cleaned when the flow does not contain the target molecules. The invention also relates to a control interface of the device.
    Type: Grant
    Filed: December 28, 2012
    Date of Patent: August 8, 2017
    Assignee: CENTRE SCIENTIFIQUE ET TECHNIQUE DU BATIMENT
    Inventors: Stéphane Moularat, Yael Joblin, Enric Robine
  • Patent number: 9719970
    Abstract: The present disclosure relates to CO2-based chromatography for the efficient and precise separation of Vitamin D metabolites.
    Type: Grant
    Filed: November 26, 2013
    Date of Patent: August 1, 2017
    Assignee: Waters Technologies Corporation
    Inventor: John Vukovic
  • Patent number: 9713652
    Abstract: Provided according to some embodiments of the invention are methods of forming co-condensed silica particles. In some embodiments, the methods include reacting a thiol-containing silane and a backbone alkoxysilane in a reaction solution that comprises water to form thiol-functionalized co-condensed silica particles, wherein the thiol-functionalized co-condensed silica particles include a polysiloxane matrix and at least some of thiol groups are present within the polysiloxane matrix; and reacting the thiol-functionalized co-condensed silica particles with a nitrosating agent to provide the S-nitrosothiol-functionalized co-condensed silica particles. In some embodiments, provided are S-nitrosothiol-functionalized co-condensed silica particles.
    Type: Grant
    Filed: August 26, 2013
    Date of Patent: July 25, 2017
    Assignees: The University of North Carolina at Chapel Hill, Novan, Inc.
    Inventors: Mark Schoenfisch, Daniel Riccio, Julia Nugent, Nathan Stasko
  • Patent number: 9709577
    Abstract: The invention relates to a method and a diagnostic kit for monitoring HIV specific T cell responses and identifying subjects capable of controlling HIV progression or preventing HIV infection altogether. The method is based on the combined use of boosted flow cytometry and toggle peptides and can cover a large set of effector functions. The method is also suitable to detect T cell responses of any desirable cytokine or combination of cytokines to any pathogen.
    Type: Grant
    Filed: March 22, 2013
    Date of Patent: July 18, 2017
    Assignees: LABORATORIOS DEL DR. ESTEVE S.A., FUNDACIO PRIVADA INSTITUT DE RECERCA DE LA SIDA—CAIXA, INSTITUCIÓ CATALANA DE RECERCA I ESTUDIOS AVANÇATS
    Inventors: Marta Ruiz Riol, Christian Brander, Javier Ibarrondo
  • Patent number: 9709565
    Abstract: The present invention provides methods of detecting infection using biomarkers. The methods disclosed herein include measuring the expression level of one of more polypeptide determinant in which the alteration of the expression level indicates infection of the patient in a sample of the subject and determining a clinically significant alteration in the level of the one or more polypeptides in the sample, wherein the alteration indicates an infection in the subject. The methods provided herein are for distinguishing between bacterial infection, mixed infection and/or viral infection.
    Type: Grant
    Filed: April 20, 2011
    Date of Patent: July 18, 2017
    Assignee: MeMed Diagnostics Ltd.
    Inventors: Eran Eden, Kfir Oved
  • Patent number: 9709575
    Abstract: The invention relates to methods and products for the identification of a clinically significant immune response in subjects treated with a therapeutic protein. A first aspect of the invention relates to methods and compositions for identifying a clinically significant immune response in patients treated with therapeutic amounts of VLA4 binding antibody (e.g., natalizumab). A second aspect of the invention concerns the chronological details of sample collection for determining the titer of antibodies against the therapeutic protein, e.g. the collection of at least two samples at two different time points. A third aspect of the invention relates to the selection of the critical threshold level, which corresponds to the antibody titer of untreated patients increased by the double of the standard deviation of this control antibody titer.
    Type: Grant
    Filed: July 14, 2014
    Date of Patent: July 18, 2017
    Assignee: Biogen MA Inc.
    Inventors: Meena Subramanyam, Lakshmi Amaravadi, Eric Wakshull, Frances Lynn, Michael Panzara, Robin McDaid Barbour, Julie Elizabeth Taylor
  • Patent number: 9701756
    Abstract: The present invention provides a humanized antibody or fragment thereof specific for the antigen CD45R0, wherein said antibody or fragment thereof comprises a humanized heavy chain variable domain comprising a CDR1 region of SEQ ID NO:1, a CDR2 region of SEQ ID NO:2, and a CDR3 region of SEQ ID NO:3, and a humanized light chain variable domain comprising a CDR1 region of SEQ ID NO:4, a CDR2 region of SEQ ID NO:5, and a CDR3 region of SEQ ID NO:6. It is also provided the use of the present antibody or fragment thereof for enrichment or depletion of CD45R0-expressing cells from a sample comprising CD45R0-expressing cells.
    Type: Grant
    Filed: November 25, 2015
    Date of Patent: July 11, 2017
    Assignee: Miltenyi Biotec GmbH
    Inventors: Holger Thie, Stefan Tomiuk, Iris Bürger, Volker Nolle
  • Patent number: 9702873
    Abstract: Molecules or particle having a hydrodynamic radius as small as 3.5 nm can be trapped using a double-nanohole structure defined in a metal film or other metallic layer. Application of a suitable optical radiation flux to the double-nanohole structure can provide a folding and/or binding of protein molecules that can be identified based on changes in optical transmission. Varying nanohole transmissions can thus be associated with trapping, binding and unfolding of biological particles. The double-nanohole defines cusps, but such cusps can be defined in other ways as well.
    Type: Grant
    Filed: August 12, 2013
    Date of Patent: July 11, 2017
    Inventors: Reuven Gordon, Yuanjie Pang
  • Patent number: 9696311
    Abstract: Sensor array for detecting biomarkers for cancer in breath samples. The sensor array is based on 2D films or 3D assemblies of conductive nanoparticles capped with an organic coating wherein the nanoparticles are characterized by a narrow size distribution. Methods of use of the sensor array for discriminating between patterns of volatile organic compounds from healthy individuals and patients with various types of cancer are disclosed.
    Type: Grant
    Filed: January 10, 2010
    Date of Patent: July 4, 2017
    Assignee: Technion Research and Development Foundation Ltd.
    Inventors: Hossam Haick, Peng Gang, Orna Adams
  • Patent number: 9695235
    Abstract: The present invention provides a composition for regulating cell proliferation comprising a peptide having a partial amino acid sequence of BBF2H7 or an antibody capable of binding to the peptide. The problem has been solved by preparation of the peptide having a partial amino acid sequence of BBF2H7 which has a cell proliferation activity.
    Type: Grant
    Filed: August 28, 2013
    Date of Patent: July 4, 2017
    Assignee: Hiroshima University
    Inventors: Kazunori Imaizumi, Atsushi Saito
  • Patent number: 9689792
    Abstract: A particle detection apparatus and method includes an excitation source having a first emission band that excites a sample and a second emission band; a first optical device connected to the excitation source and attenuates radiation emitted in the second emission band; an optical cavity adjacent to the first optical device, which includes a sample excited by radiation from the excitation source; a substrate coupled to the optical cavity and exposed to the radiation from the excitation source; a binding compound coupled to the substrate, which includes a ligand coupled to the substrate; and a capture material coupled to the ligand and capturing the sample; a second optical device connected to the substrate and attenuates radiation emitted in the first emission band; and an optical detector connected to the second optical device and detects radiation emitted in the second emission band.
    Type: Grant
    Filed: January 20, 2011
    Date of Patent: June 27, 2017
    Assignee: The United States of America as Represented by the Secretary of the Army
    Inventors: David W. Sickenberger, Christopher J. Karwacki
  • Patent number: 9682071
    Abstract: The disclosure relates to methods of preserving or improving microvascular integrity in a patient in need thereof comprising administering pirfenidone therapy to the patient.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: June 20, 2017
    Assignees: INTERMUNE, INC., THE BOARD OF TRUSTEES OF THE LELAND STANFORD
    Inventors: Mark R. Nicolls, Karl Kossen, Alan Cohen
  • Patent number: 9682118
    Abstract: A compound including a cell penetrating peptide (CPP) and elastin-like polypeptide (ELP), and a method for use thereof, are useful for inhibiting the proliferation of cancer.
    Type: Grant
    Filed: May 27, 2010
    Date of Patent: June 20, 2017
    Assignee: University of Mississippi Medical Center
    Inventors: Drazen Raucher, Gene Bidwell, III
  • Patent number: 9683993
    Abstract: The present invention relates generally to microfluidic structures, and more specifically, to microfluidic structures and methods including meandering and wide channels. Microfluidic systems can provide an advantageous environment for performing various reactions and analyses due to a reduction in sample and reagent quantities that are required, a reduction in the size of the operating system, and a decrease in reaction time compared to conventional systems. Unfortunately, the small size of microfluidic channels can sometimes result in difficulty in detecting a species without magnifying optics (such as a microscope or a photomultiplier). A series of tightly packed microchannels, i.e., a meandering region, or a wide channel having a dimension on the order of millimeters, can serve as a solution to this problem by creating a wide measurement area.
    Type: Grant
    Filed: April 10, 2013
    Date of Patent: June 20, 2017
    Assignees: President and Fellows of Harvard College, OPKO Diagnostics, LLC
    Inventors: Vincent Linder, Samuel K. Sia, George M. Whitesides, Max Narovlyansky, Adam Carlyn Siegel
  • Patent number: 9678089
    Abstract: Methods and kits for measuring levels of von Willebrand factor function in a sample without using a platelet aggregation agonist, such as ristocetin, comprising recombinant glycoprotein Ib? having a combination of G233V, D235Y and M239V mutations and an agent to detect a complex between the recombinant glycoprotein Ib? and von Willebrand factor.
    Type: Grant
    Filed: September 15, 2014
    Date of Patent: June 13, 2017
    Assignees: BLOOD CENTER RESEARCH FOUNDATION, THE MEDICAL COLLEGE OF WISCONSIN, INC.
    Inventor: Robert Montgomery
  • Patent number: 9677105
    Abstract: Polypeptide preparations having target levels of glycans, and methods of producing such polypeptide preparations using ammonium and/or lysine, are described.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: June 13, 2017
    Assignee: Momenta Pharmaceuticals, Inc.
    Inventors: Brian Edward Collins, Holly Prentice, Brett Belongia, Rasheed Tijani
  • Patent number: 9676861
    Abstract: The present invention provides high affinity anti-CD40 monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of cancer and other diseases.
    Type: Grant
    Filed: October 30, 2013
    Date of Patent: June 13, 2017
    Assignee: Apexigen, Inc.
    Inventors: Yongke Zhang, Guo-Liang Yu, Weimin Zhu
  • Patent number: 9676862
    Abstract: The present invention relates to antibodies (and fragments, variants, fusions and derivatives thereof) with multivalent binding specificity for CD40, which have a potency for dendritic cell activation which is higher than, or is equal to, the potency for B cell activation and wherein the antibody, antigen-binding fragment, or fusion, variant or derivative thereof has an affinity (KD) for CD40 of less than 1×10?10 M, which have utility in the treatment of diseases such as cancer. The invention also relates to pharmaceutical compositions, uses, methods and kits comprising such antibodies.
    Type: Grant
    Filed: September 5, 2012
    Date of Patent: June 13, 2017
    Assignee: ALLIGATOR BIOSCIENCE, AB
    Inventors: Peter Bo Joakim Ellmark, Eva Maria Dahlen
  • Patent number: 9678062
    Abstract: Methods of expanding FCs or stem cells are provided herein, as are methods of screening for compounds that increase expression of DOCK2 or decrease expression of Arhgap18, either of which improves engraftment.
    Type: Grant
    Filed: September 21, 2012
    Date of Patent: June 13, 2017
    Assignee: University of Louisville Research Foundation, Inc.
    Inventors: Suzanne T. Ildstad, Mary Jane Elliott
  • Patent number: 9678084
    Abstract: Compositions and methods related to diagnosis of ear infections and acute otitis media.
    Type: Grant
    Filed: June 4, 2012
    Date of Patent: June 13, 2017
    Assignee: Rochester General Hospital Research Institute
    Inventors: Michael Pichichero, Kyle Liu
  • Patent number: 9671366
    Abstract: One embodiment of the invention provides a system adapted and configured to generate a localized flow circulation zone. The system includes: a free-standing microfluidic pipette comprising three or more channels with exits separated from each other by an outer surface of the pipette; and a controller programmed to control fluid flows through each of the three or more channels to generate a localized recirculating fluid flow path outside the pipette. Liquid leaving the microfluidic pipette through at least one outlet channel exit is withdrawn through at least two inlet channel exits.
    Type: Grant
    Filed: August 11, 2015
    Date of Patent: June 6, 2017
    Assignee: Fluicell AB
    Inventors: Owe Orwar, Alar Ainla, Aldo Jesorka
  • Patent number: 9664689
    Abstract: The present invention provides an immunodiagnostic method for determining procalcitonin and procalcitonin derivatives in a biological sample of a patient, in particular in the monitoring and control of treatment and the monitoring of the progression of a local or systemic bacterial infection, inflammation, sepsis or neurodegenerative disease. In particular, the method detects molecular forms of intact procalcitonin 1-116, or procalcitonin partial peptides derived therefrom that retain amino acids alanine and proline (Ala-Pro, AP) in positions 1 and 2 of the amino terminus of the complete procalcitonin 1-116. The method uses antibodies that selectively bind an epitope comprising amino acids 1 and 2 of procalcitonin 1-116 (SEQ ID NO: 1) and can distinguish between intact procalcitonin 1-116 and for example, procalcitonin 3-116.
    Type: Grant
    Filed: January 14, 2013
    Date of Patent: May 30, 2017
    Assignee: B.R.A.H.M.S GMBH
    Inventors: Andreas Bergmann, Joachim Struck
  • Patent number: 9664695
    Abstract: A method for (a) diagnosing or monitoring kidney function in subject or (b) diagnosing kidney dysfunction in a subject or (c) predicting or monitoring the risk of an adverse events in a diseased subject or (d) predicting or monitoring the success of a therapy or intervention comprising determining the level of Pro-Enkephalin (PENK) or fragments thereof of at least 5 amino acids in a bodily fluid obtained from said subject; and correlating said level of Pro-Enkephalin or fragments thereof with (a) kidney function in a subject or (b) kidney dysfunction in said subject or (c) enhanced risk of adverse events or (d) success of a therapy or intervention in a diseased subject.
    Type: Grant
    Filed: October 1, 2013
    Date of Patent: May 30, 2017
    Assignee: Sphingotec GmbH
    Inventor: Andreas Bergmann
  • Patent number: 9664680
    Abstract: The present invention relates to methods of diagnosing and/or prognosing proliferative disorders, especially brain cancers (e.g. gliomas). In particular, the present invention provides a means to conveniently detect malignant tumours merely by assaying or analysing blood (particularly blood serum). Cytokines and/or angiogenesis factors in blood serum have been found to be surprisingly powerful at indicating the presence of brain cancers in a subject. Moreover, spectroscopic analysis, especially ATR-FTIR analysis, of a blood sample has been demonstrated to be surprisingly effective at producing a signature that can be correlated with the presence, extent, severity, or aggressiveness of malignant tumours in a subject.
    Type: Grant
    Filed: March 3, 2016
    Date of Patent: May 30, 2017
    Inventors: Matthew James Baker, Peter Abel, Robert William Lea
  • Patent number: 9655963
    Abstract: Provided are methods of diagnosing IgA nephropathy in a subject. Optionally, the methods comprise isolating an IgG from the subject and determining whether the IgG binds to a galactose-deficient IgA1. Optionally, the methods comprise providing a biological sample from the subject and detecting in the sample a mutation in a IGH gene, wherein the mutation is in a nucleotide sequence encoding a complementarity determining region 3 (CDR3) of a IGH variable region. Optionally, the methods comprise determining a level of IgG specific for a galactose-deficient IgA1 in the subject. Also provided are methods of treating or reducing the risk of developing IgA nephropathy in a subject.
    Type: Grant
    Filed: June 27, 2014
    Date of Patent: May 23, 2017
    Assignees: The UAB Research Foundation, US Army Walter Reed Army Medical Center, Chief, Office Of Research, Marketing & Policy Dev Walter Reed Army Institute of Research, Juntendo University School of Medicine, Division of Nephrology, Department of Internal Medicine, University of Tennessee Research Foundation
    Inventors: Hitoshi Suzuki, Run Fan, Bruce A. Julian, Jan Novak, Zina Moldoveanu, Zhixin Zhang, Milan Tomana, Jiri Mestecky, Robert J. Wyatt, Yasuhiko Tomino, Yusuke Suzuki, Stephen Olson, Matthew B. Renfrow
  • Patent number: 9657055
    Abstract: The invention discloses a polypeptide capable of binding immunoglobulins or immunoglobulin-containing proteins, which polypeptide comprises six or more domains of protein Z or the C domain of protein A or a functional variant thereof. It also discloses separation matrices comprising the polypeptide and methods of using the separation matrices for separation of immunoglobulins or immunoglobulin-containing proteins.
    Type: Grant
    Filed: November 28, 2012
    Date of Patent: May 23, 2017
    Assignee: GE Healthcare BioProcess R&D AB
    Inventors: Hans J. Johansson, Ronnie Palmgren
  • Patent number: 9658142
    Abstract: Methods and apparatuses are provided for extraction and collection of sets of one or more cells from a formalin-fixed paraffin embedded tissue sample. A laser is used to remove sets of one or more cells from an immobilized sample within a microfluidic device, and a fluid flow element washes the removed set of one or more cells away from the immobilized sample, preferably to be collected in a downstream sample collection device. Morphological and/or positional information may be preserved to permit at least one technique (e.g., amplification, sequencing, and/or analytical, optionally performed after cells are lysed downstream of the microfluidic device) to be related to the original spatial location of the set of one or more cells in the immobilized sample.
    Type: Grant
    Filed: April 14, 2016
    Date of Patent: May 23, 2017
    Assignee: Arizona Board of Regents on behalf of Arizona State University
    Inventors: David Richardson, Thai Tran, Dmitry Derkach, Colleen Ziegler
  • Patent number: 9645101
    Abstract: Methods for detection and identification of bacteria within a sample include the step of inserting a pair of electrodes into the sample. A first impedance across the electrodes is established with a first AC voltage source having a first frequency. A phage is introduced into the sample, and impedance fluctuations that are caused by ion release by the bacteria due to the phage introduction are measured. The use of impedance fluctuations instead of voltage fluctuations to detect and identify bacteria minimizes 1/f noise effects and increases system sensitivity. To further increase system sensitivity by eliminating thermal noise, a second impedance across the electrodes can be established using a second AC voltage source at a second frequency. Second impedance fluctuations are cross-correlated to the first impedance fluctuations, and the cross-correlation results are analyzed to determine whether or not bacteria are present in the sample based on phage electrical activity.
    Type: Grant
    Filed: July 8, 2013
    Date of Patent: May 9, 2017
    Assignee: The United States of America, as Represented by the Secretary of the Navy
    Inventors: Gabor Schmera, Laszlo Kish
  • Patent number: 9644027
    Abstract: This invention features antibodies that specifically bind to a murine Dragon family protein.
    Type: Grant
    Filed: March 3, 2015
    Date of Patent: May 9, 2017
    Assignee: The General Hospital Corporation
    Inventors: Clifford J. Woolf, Tarek A. Samad
  • Patent number: 9632077
    Abstract: A detection system of a test substance, includes: a magnetic body that is modified by a first substance capable of being bound to the test substance at a first binding site of the test substance; a marker that is modified by a second substance capable of being bound to the test substance at a second binding site of the test substance, the second coupling site being a different site from the first binding site; a development medium that has a flow passage into which liquid, in which the magnetic body and the marker is dispersed, flows due to a capillary phenomenon, the development medium having a detection position for detecting the marker in a portion of the flow passage, the development medium having light transparency at least in the detection position; and a magnetic force generating portion that is equipped in the development medium.
    Type: Grant
    Filed: January 5, 2015
    Date of Patent: April 25, 2017
    Assignees: TOPPAN PRINTING CO., LTD., TOKYO INSTITUTE OF TECHNOLOGY
    Inventors: Takumi Hirase, Masato Nakayama, Hiroshi Handa, Satoshi Sakamoto, Yasuyuki Naito
  • Patent number: 9623085
    Abstract: Therapeutic compositions containing chimeric natriuretic peptides for treating chronic kidney disease alone, heart failure alone, or chronic kidney disease with concomitant heart failure are described. The therapeutic compositions have enhanced stability characteristics to facilitate storage and delivery by provisioning apparatuses under conditions of elevated temperature and mechanical stress. Methods for increasing the stability of therapeutic compositions containing chimeric natriuretic peptides are further described.
    Type: Grant
    Filed: November 6, 2015
    Date of Patent: April 18, 2017
    Assignee: Capricor Therapeutics, Inc.
    Inventors: William Van Antwerp, Andrew J. L. Walsh, Lian Luo, Dianne L. Judd
  • Patent number: 9624305
    Abstract: Methods are provided to manipulate phagocytosis of cancer cells, including e.g. leukemias, solid tumors including carcinomas, etc.
    Type: Grant
    Filed: February 26, 2016
    Date of Patent: April 18, 2017
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Siddhartha Jaiswal, Irving L. Weissman, Ravindra Majeti, Mark P. Chao